NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment (NCT06537154)
Active Surveillance Versus Definitive Local Therapy for Patients Showing Clinical Complete Response Following Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
🩺 Plain-English Summary (8th-Grade Level)
Invasive bladder cancer is managed with neoadjuvant therapy followed by bladder removal (cystectomy). Research shows that approximately 40% of patient will have no remaining cancer left in their bladder after completion of the initial systemic treatment, and perhaps could have avoided the surgery. However, currently physicians lack the ability to identify these patients. The investigators believe that by using advanced imaging (MRI), bladder biopsies and novel biomarkers that detect tumor DNA in blood, they can better identify participants without any remaining cancer after chemotherapy. This will make active surveillance of these participants safer. In this study, participants without evidence of residual cancer will be randomized to active surveillance vs conventional bladder treatment (bladder removal, or chemo-radiation of the bladder). This study will be a pilot randomized control trial (RCT), and if successful, it will transition to a larger phase 3 RCT.
Who can join: Review the eligibility criteria below.
Location: Vancouver Prostate Centre — Vancouver, British Columbia
Age range: 19 Years
🧪 Interventions in This Study
- Active Surveillance (PROCEDURE)
- Control arm - Definitive bladder treatment (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Vancouver Prostate Centre — Vancouver, British Columbia
📞 Contact the Study Coordinator
Phone: (604) 875-5003
Email: mst-laurent@prostatecentre.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Muscle-Invasive Bladder Carcinoma
- A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer — Chapel Hill, North Carolina
- Prophylactic Antibiotics in Cystectomy With Diversion — Minneapolis, Minnesota
- Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease — Orlando, Florida
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors — Santa Monica, California
- Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology — Los Angeles, California
Explore by condition: All Muscle-Invasive Bladder Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.